What Changes in EMA GVP Module III Revision 2?
GVP Module III Revision 2 took effect on 10 September 2026. See what changes for subcontractor oversight, PSMF access, remote inspections, and risk planning.
Clinical Trials in Depression Reveal New R&D Priorities in 2026
Clinical trials in depression reveal a broader R&D landscape, from antidepressants and NMDA approaches to biological data and precision psychiatry.
Ivonescimab Challenges Keytruda Beyond China
Ivonescimab beat pembrolizumab in a Chinese trial. Pharmatica examines what HARMONi-2 means for global clinical development, trial design, and NSCLC treatment.
An Overview of EuroQol EQ-5D: Quality-of-Life Assessment
EuroQol EQ-5D explained: How it measures quality of life, supports QALYs and HTA decisions, and what new EuroQol tools mean for clinical trial strategy.